Nitin Wadhwani

Associate Professor

Ann and Robert H Lurie Children's Hospital of Chicago
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Atypical Teratoid/Rhabdoid Tumor (AT/RT) is a highly aggressive neoplasm of the central nervous system (CNS), most commonly affecting infants and young children. Originally recognized as a distinct entity following cytogenetic identification of monosomy 22 in renal Rhabdoid Tumors, AT/RT now encompasses CNS tumors characterized by SMARCB1 (INI-1) or SMARCA4 (BRG-1) alterations within the SWI/SNF chromatin-remodeling complex. The integration of immunohistochemical markers with advanced molecular diagnostics—including next-generation sequencing, DNA methylation profiling, and gene enrichment analyses—has facilitated robust tumor classification and the identification of three molecular subgroups: TYR, SHH, and MYC. Despite its distinctive histopathologic features, AT/RT remains diagnostically challenging in adolescent and adult populations due to age-related bias and potential morphologic heterogeneity. Differential considerations, including epithelioid sarcoma, poorly differentiated chordoma, CRINET, choroid plexus carcinoma, and rare composite tumors, further complicate the diagnostic landscape. A comprehensive, multimodal diagnostic approach combining histologic, immunophenotypic, and molecular data is essential to accurately identify AT/RT and guide clinical management, particularly in diagnostically ambiguous or atypical cases.

Year:

2025

Atypical teratoid/rhabdoid tumors (AT/RT) are malignant central nervous system (CNS) tumors. Typically, AT/RT is classified as SMARCB1 (INI-1) deficient or as SMARCA4 (BRG1) deficient. In this case, we describe a unique case of AT/RT with a novel SMARCA4 missense variant identified on next-generation sequencing but retained expression of INI-1 and BRG-1 on immunohistochemistry. Diagnosis of the tumor and discovery of the novel SMARCA4 variant was only possible after comprehensive tumor molecular testing tailored for pediatric malignancies. This case highlights the importance of molecular genetic testing as part of a workup in neoplasms concerning for possible AT/RT.

Year:

2025

Little is known about the genomic alterations in chordoma, with the exception of loss of SMARCB1, a core member of the SWI/SNF complex, in poorly differentiated chordomas. A TBXT duplication and rs2305089 polymorphism, located at 6q27, are known genetic susceptibility loci. A comprehensive genomic analysis of the nuclear and mitochondrial genomes in pediatric chordoma has not yet been reported. In this study, we performed WES and mtDNA genome sequencing on 29 chordomas from 23 pediatric patients. Findings were compared with that from whole-genome sequencing datasets of 80 adult patients with skull base chordoma. In the pediatric chordoma cohort, 81% of the somatic mtDNA mutations were observed in NADH complex genes, which is significantly enriched compared with the rest of the mtDNA genes (P = 0.001). In adult chordomas, mtDNA mutations were also enriched in the NADH complex genes (P < 0.0001). Furthermore, a progressive increase in heteroplasmy of nonsynonymous mtDNA mutations was noted in patients with multiple tumors (P = 0.0007). In the nuclear genome, rare likely germline in-frame indels in ARID1B, a member of the SWI/SNF complex located at 6q25.3, were observed in five pediatric patients (22%) and four patients in the adult cohort (5%). The frequency of rare ARID1B indels in the pediatric cohort is significantly higher than that in the adult cohort (P = 0.0236, Fisher’s exact test), but they were both significantly higher than that in the ethnicity-matched populations (P < 5.9e−07 and P < 0.0001174, respectively). Implications: germline ARID1B indels and mtDNA aberrations seem important for chordoma genesis, especially in pediatric chordoma.

Year:

2024

Year:

2024

Year:

2024

Background The gift of postmortem tissue donation is critical to pediatric central nervous system (CNS) research. As a “Center of Excellence” for the Gift from a Child Program, our institution has a well‐established postmortem tissue donation program. Our objective was to determine if differences exist between patients who participated in and those that declined research‐based autopsy. Procedure We performed a single‐institution retrospective chart review of pediatric patients with CNS malignancies who died from their disease between January 1, 2021 and December 31, 2022. Individual clinical, demographic, and socioeconomic data were assessed. Population‐level data were estimated using Zip Code Tabulation Areas. Descriptive statistics were used to compare categorical data. Results Among the 23 patient families approached during the study time frame, 8/23 (35%) consented to participation. In the consented (C) versus declined (D) group, there was a higher percentage of White, non‐Hispanic/Latino patients by self‐reported race (C: 88% vs. D: 55%), and no patients who identified as Asian or Hispanic/Latino (C: 0% and 0% vs. D: 13% and 27%). Of all patients approached, two required interpreters (9%), and both families declined participation. The rate of private insurance was higher in the consented group (C: 75% vs. D: 47%) compared to Medicaid as primary insurance in the declined group (C: 13% vs. D: 53%). Conclusions Future research should aim to understand and improve identified disparities to ensure research advancements benefit all children with CNS malignancies. One area we plan to address is improved communication with non‐English‐speaking families by partnering with our interpreter services.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (13)

Judith Kabat

Assistant Professor

University of Louisville

UNITED STATES
View details

Hesamedin Hakimjavadi

Assistant Professor

Medical College of Wisconsin

UNITED STATES
View details

Angela Waanders

Associate Professor

Ann and Robert H Lurie Children's Hospital of Chicago

UNITED STATES
View details

Pamela Rathbun

Assistant Professor

Northwestern Medicine

UNITED STATES
View details

Jared Ahrendsen

Assistant Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Declan McGuone

Associate Professor

Yale University

UNITED STATES
View details

Kai Lee Yap

Assistant Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Jennifer Cotter

Assistant Professor of Clinical Pathology

University of Southern California Norris Comprehensive Cancer Center

UNITED STATES
View details

John Wilson

Assistant Professor

Indiana University School of Medicine

UNITED STATES
View details

Xiaowu gai

Professor

Medical College of Wisconsin

UNITED STATES
View details

Jaclyn Biegel

Professor of Clinical Pathology

Children's Hospital of Los Angeles

UNITED STATES
View details

James Ross

Assistant Professor

University of Virginia

UNITED STATES
View details

Nadejda Tsankova

Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details